CyBio and Axxam Develop a New System for High Throughput Screening

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Expanding capabilities in robotic HTS

Jena, Germany and Milan, Italy, March 20th 2009 - CyBio AG and Axxam
SpA announce that they have developed, installed and fully validated
a new state-of-the-art screening station to be used by Axxam in
running hit discovery campaigns with automated luminescence and
fluorescence screening systems.

CyBio AG is a worldwide leading life science company. As an
innovative technology provider CyBio develops, produces and markets
technology platforms for drug discovery. With more than 20 years of
experience CyBio establishes new standards for precision, speed and
engineering with its hardware, software and service products for the
automation of drug screening processes.

Axxam SpA is a leading discovery company that offers early-stage
discovery services, technologies and lead discovery programs for
application in the life science industry. Core expertises are based
on target-based screening approaches.

The new workstation, which will run in parallel to another CyBio
workstation, is a customized, multi-functional automation platform
that allows flexible adaptation to different assay conditions using
high-density 384 plates.
A central CyBi®-Well vario high parallel pipetting system unites two
major working areas. Cooled storage system, peeler, sealer and plate
heating stations frame the area for compound management. The
screening area not only consists of a pipetting system, a dispenser,
a washer, high-capacity stacking and incubation devices with lid
handling options, but also of two readers, a FLIPRTETRA (Molecular
Device) and a PHERAstarPlus (BMG Labtech). They can be used to
acquire fluorescent or luminescent readouts, both in cell-based or
biochemical assays.
All modules are integrated by a Stäubli 6-axis robot and a KiNEDx
4-axis robot that ensure high speed and precision in plate transfers.
The system as a whole is controlled by the CyBio® Scheduler software
that manages automatic parallelization of processes, consistent
system utilization and time uniformity across screening.
This results in very high consistency in assay performance and in a
throughput that ranges from 35,000 for long acquisition-time readings
to 47,000 test points per day.
Axxam will benefit from broader access to automated high throughput
screening (uHTS) and will consolidate its leading position as an
important discovery partner for target-based screening discovery
programs.

About Axxam

Axxam is a leading discovery company that offers early-stage
discovery services, technologies and lead discovery programs for
application in the life science industry.
Our tools, core technologies and activities include a wide range of
screening assays, specific assay development, high-throughput
screening (HTS) campaigns, compound profiling and hit-to-lead
activities. Axxam also provides access to several compound
collections and conducts internal discovery programs for selected
targets which are also carried out in partnership with life science
companies.
A team of almost 70 qualified personnel is committed to advance the
discovery projects of our partners. The scientific know-how of our
team is built upon years of experience as part of the Bayer
HealthCare, Research and Development organization prior to the late
2001 inauguration of Axxam as an independent private company. The
growing list of our collaborations in the life science industry is
the recognition of our success in areas such as the pharmaceutical,
agrochemical, fragrance, cosmetic, flavour, food and beverage
branches. Axxam is a privately-owned company with offices and
state-of-the-art laboratories located in the San Raffaele Biomedical
Science Park, Milan.

Further information on Axxam can be found at www.axxam.com

About CyBio

With almost 20 years of experience, CyBio is a leading player of high
quality liquid handling technologies. In the pharmaceutical and life
science industries, CyBio's products enjoy the highest reputation for
precision, reliability and simplicity. From standalone CyBi®-Well
pipettors up to fully customized solutions CyBio provides reliable,
precise and user-friendly automated systems for a wide range of
application and throughput needs in Life Sciences and Drug Discovery
research. Moreover, CyBio's Customized Solutions Team designs,
produces and installs fully automated systems tailored to client's
application, throughput and capacity requirements.
Headquartered in Jena, Germany, CyBio employs more than 150 employees
worldwide. Its products are sold by a dedicated sales force and a
global network of distributors. CyBio's clients are leading
pharmaceutical and biotechnology companies, as well as academic
research institutes.

Visit www.cybio-ag.com for more information.

Further Information:

Alessandro Sidoli
Chief Executive Officer
Axxam SpA
Phone: +39 (0)2 2105687
Fax: +39 (0)2 2105602
Email: info@axxam.com

Tina Fröhlich
Director Marketing
CyBio AG
Phone: +49 3641 351 350
Fax: +49.3641.351 478
Email: info@cybio-ag.com

--- End of Message ---

CyBio AG
Göschwitzer Straße 40 Jena Germany

WKN: 541230; ISIN:
DE0005412308; Index: CDAX;
Listed: General Standard in Frankfurter Wertpapierbörse, Freiverkehr
in Bayerische Börse München,
Freiverkehr in Börse Stuttgart, Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische
Wertpapierbörse zu Hamburg,
Freiverkehr in Niedersächsische Börse zu Hannover, Regulierter Markt
in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2009. All rights reserved.